Search Result

Results for "

GluR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (2) Aminoacyl-tRNA Synthetase (1) AMPK (1) Apoptosis (1) Bacterial (1) Calcium Channel (7) Carbonic Anhydrase (7) GABA Receptor (7) GCGR (3) HIV (1) iGluR (32) Isotope-Labeled Compounds (2) mGluR (1) PKC (2) Potassium Channel (7) Reference Standards (2) Sodium Channel (7)
By Research Areas:	Cardiovascular Disease (1) Infection (1) Metabolic Disease (3) Neurological Disease (35)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147132

GluR6 antagonist-1	iGluR	Neurological Disease
GluR6 antagonist-1 is a benzothiophene derivative, acting as a *GluR6* antagonist. GluR6 antagonist-1 can be used for researching acute and chronic neurological disorders .

HY-P4106A

*Tat-GluR23Y, scrambled TFA* 1 Publications Verification	Amino Acid Derivatives	Neurological Disease
Tat-GluR23Y, scrambled TFA is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .

HY-101261

ATPA	iGluR	Neurological Disease
ATPA is a selective glutamate receptor *GluR5* activator with EC₅₀s of 0.66, 9.5, 1.4, 23, 32, 18, and 14 μM for GluR5wt, GluR5(S741M), GluR5(S721T), GluR5(S721T, S741M), GluR5(S741A), GluR5(S741L), and GluR5(S741V), respectively .

HY-13456

LY-404187	iGluR	Neurological Disease
LY-404187 is a potent, selective and centrally active positive allosteric modulator of AMPA receptors, with the EC₅₀s of 5.65, 0.15, 1.44, 1.66 and 0.21 µM for *GluR1i, GluR2i, GluR2o, GluR3i* and *GluR4i*, respectively. LY-404187 has therapeutic potential in a number of psychiatric disorders and neurodegenerative diseases .

HY-P5487

GluR23Y	iGluR	Others
GluR23Y is a biological active peptide. (This GluR23Y peptide was used in ELISA cell-surface assay for the insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y prevented any insulin-induced reduction. The blockade of insulin action was observed when the GluR23Y peptide was delivered into neurons by fusing it to the membrane transduction domain of HIV-1.)

HY-P10401

*TAT-GluR6-9c*	Apoptosis iGluR	Cardiovascular Disease Neurological Disease
TAT-GluR6-9c is a *GluR6-PSD95* interaction blocker. By regulating the *GluR6* mediated signaling pathway, TAT-GluR6-9c inhibits the activation of JNK and phosphorylation of c-Jun, reduces the expression of Fas L and thus reduces the occurrence of apoptosis. TAT-GluR6-9c can be used to study cerebral ischemia and neuroprotective strategies .

HY-P5395

*TAT-GluR23A Fusion Peptide*	HIV	Others
TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)

HY-P4106

*Tat-GluR23Y, scrambled*	Amino Acid Derivatives	Neurological Disease
Tat-GluR23Y, scrambled is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .

HY-176297

Tezampanel etibutil	AMPK iGluR	Neurological Disease
Tezampanel etibutil is an orally active *AMPA/GluR* antagonist. Tezampanel etibutil can be used in the research of pain, migraine, and neurological disorders .

HY-148828

LSP-GR3	iGluR	Neurological Disease
LSP-GR3 is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate *GluR* alternative splicing to GluR3-flip expression throughout the CNS.

HY-148828A

LSP-GR3 sodium	iGluR	Neurological Disease
LSP-GR3 sodium is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate *GluR* alternative splicing to GluR3-flip expression throughout the CNS.

HY-19433A

(S)-ATPO	iGluR	Neurological Disease
(S)-ATPO is the (S)-enantiomer of ATPO, which is a competitive antagonist at GluR1-4 (AMPA-preferring) receptors .

HY-104020A

Philanthotoxin 74 dihydrochloride PhTx 74 dihydrochloride	iGluR	Neurological Disease
Philanthotoxin 74 dihydrochloride (PhTx 74) is an AMPAR antagonist; inhibits *GluR3* and *GluR1* with IC₅₀s of 263 and 296 nM, respectively .

HY-104020B

Philanthotoxin 74 diTFA PhTx 74 diTFA	iGluR	Neurological Disease
Philanthotoxin 74 (PhTx 74) diTFA is an AMPAR antagonist; inhibits *GluR3* and *GluR1* with IC₅₀s of 263 and 296 nM, respectively .

HY-12509

PEPA	iGluR	Neurological Disease
PEPA is an AMPA receptor allosteric potentiator. PEPA shows preferential action of PEPA on the flop form of AMPA receptors. PEPA is a more potent suppressor of desensitization of receptors containing GluR3 and GluR4 as opposed to those containing GluR1. PEPA has antianxiety effects .

HY-114427

NS-102 1 Publications Verification	iGluR	Neurological Disease
NS-102 is a selective kainate (GluK2) receptor antagonist. NS-102 is a potent *GluR6/7* receptor antagonist .

HY-107602

UBP310	iGluR	Neurological Disease
UBP310 is a selective *GluR5* antagonist, with a K_d of 130 nM .

HY-P1195

PDZ1 Domain inhibitor peptide	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P1195A

PDZ1 Domain inhibitor peptide TFA	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-101528

IDRA 21	iGluR	Neurological Disease
IDRA 21 is a positive and orally active modulator of the AMPA receptor. IDRA 21 facilitates excitatory neurotransmission via GluR1/2 receptors. IDRA 21 has the potential for the research of cognitive/memory disorders, including those associated with aging .

HY-103229

Cl-HIBO	iGluR	Neurological Disease
Cl-HIBO is a highly subtype-selective *GluR1/2* agonist (EC₅₀=4.7 and 1.7 μM, respectively). Cl-HIBO is a potent AMPA receptor agonist (IC₅₀=0.22 μM). Cl-HIBO has desensitizing properties .

HY-159628A

Glu-AMS TEA	Aminoacyl-tRNA Synthetase Bacterial	Infection
Glu-AMS TEA is a competitive inhibitor of Escherichia coli glutamyl-tRNA synthetase (GluRS), with the K_i of 2.8 nM .

HY-120386

LY382884	iGluR	Neurological Disease
LY382884 is a selective antagonist for *GluR5* kainate receptor. LY382884 prevents the induction of NMDA receptor independent long-term potentiation (LTP) .

HY-19904

Adomeglivant 4 Publications Verification LY2409021	GCGR	Metabolic Disease
Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus .

HY-114550

LY339434	iGluR	Neurological Disease
LY339434 is a potent and selective agonist for the hydrochloride receptor *GluR5*. LY339434 affects the rapid death of neurons through n-methyl-D-aspartate (NMDA) receptors .

HY-P1055

Pep2-SVKE	iGluR	Neurological Disease
Pep2-SVKE is an inactive control peptide for pep2-SVKI (HY-P1056). Pep2-SVKE is an inhibitory peptide corresponding to the last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. Pep2-SVKE does not block AMPA-mediated [ ³H]DA exocytosis. Pep2-SVKE does not bind to GRIP or PICK43 and does not block retention of PICK1 by GST-GluR2 and LTD ^{[1] [2] [3] [4] [5]}.

HY-19904R

Adomeglivant (Standard)	GCGR	Metabolic Disease
Adomeglivant (Standard) is the analytical standard of Adomeglivant. This product is intended for research and analytical applications. Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus .

HY-107604

UBP 302 1 Publications Verification	iGluR	Neurological Disease
UBP 302 is a potent and selective GLUK5-subunit containing kainate receptor antagonist (apparent K_d=402 nM), and displays very little affinity on GluK2 (GluR6) kainate receptors. Anxiolytic effects .

HY-P3504

Efinopegdutide JNJ-64565111; HM12525A; MK-6024	GCGR iGluR	Metabolic Disease
Efinopegdutide (JNJ-64565111) is a potent dual glucagon-like peptide-1 (GLP-1)/glucagon receptor (GluR) agonist, which activates both the GLP-1 and glucagon receptors. Efinopegdutide can be used in research of nonalcoholic steatohepatitis (NASH) .

HY-B0122

Topiramate Maximum Cited Publications 8 Publications Verification McN 4853; RWJ 17021	iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-107601

UBP316 ACET	iGluR	Neurological Disease
UBP316 (ACET) is a highly potent and selective kainate receptor GluK1 (GluR5) antagonist, with a K_b value of 1.4 nM. UBP316 is effective at blocking the depression of both field excitatory postsynaptic potentials (fEPSPs) and monosynaptically-evoked GABAergic transmission induced by ATPA, a GluK1 selective agonist .

HY-B0122A

Topiramate lithium McN 4853 lithium; RWJ 17021 lithium	iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-110234

Topiramate D12 McN 4853 D12 ; RWJ 17021 D12	iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-B0122S1

Topiramate-13C McN 4853-¹³C_{; RWJ 17021-¹³C}	Isotope-Labeled Compounds iGluR Potassium Channel Sodium Channel GABA Receptor Calcium Channel Carbonic Anhydrase	Neurological Disease
Topiramate- ¹³C (McN 4853- ¹³C) is ¹³C labeled Topiramate. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-100840

(S)-4C3HPG (S)-4-Carboxy-3-hydroxyphenylglycine	mGluR	Neurological Disease
(S)-4C3HPG ((S)-4-Carboxy-3-hydroxyphenylglycine) is an antagonist of metabotropic glutamate receptor 1a (mGluR 1a) and an agonist of *GluR2*. (S)-4C3HPG has the anticonvulsant activity and protects against audiogenic seizures in DBA/2 mice .

HY-B0122R

Topiramate (Standard) McN 4853 (Standard); RWJ 17021 (Standard)	Reference Standards iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate (Standard) is the analytical standard of Topiramate. This product is intended for research and analytical applications. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-P1399

Pep2m, myristoylated Myr-Pep2m	PKC	Neurological Disease
Pep2m, myristoylated (Myr-Pep2m) is a cell-permeable peptide. Pep2m, myristoylated can disrupt the protein kinase ζ (PKMζ) downstream targets, *N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions*. PKMζ is an autonomously active isozyme of protein kinase C (PKC) .

HY-P1399A

Pep2m, myristoylated TFA Myr-Pep2m TFA	PKC	Neurological Disease
Pep2m, myristoylated TFA (Myr-Pep2m TFA) is a cell-permeable peptide. Pep2m, myristoylated TFA can disrupt the protein kinase ζ (PKMζ) downstream targets, *N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions*. PKMζ is an autonomously active isozyme of protein kinase C (PKC) .

HY-B0122S

Topiramate-13C6 McN 4853-¹³C₆; RWJ 17021-¹³C₆	Isotope-Labeled Compounds Potassium Channel iGluR Sodium Channel GABA Receptor Carbonic Anhydrase Calcium Channel	Neurological Disease
Topiramate-13C6 (McN 4853-13C6) is the ¹³C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-110234R

Topiramate D12 (Standard) McN 4853 D12 (Standard); RWJ 17021 D12 (Standard)	Reference Standards iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate D12 (Standard) is the analytical standard of Topiramate D12. This product is intended for research and analytical applications. Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-P1059

Pep2-AVKI	iGluR	Neurological Disease
Pep2-AVKI is a selective peptide inhibitor of the binding of the AMPA receptor subunit (GluR2) at the C-terminal PDZ site to C-kinase (PICK1). Pep2-AVKI does not affect the binding of (AMPA-type glutamate receptor) GluA2 to GRIP or ABP. Pep2-AVKI does not increase the amplitude of AMPA currents. pep2-AVKI can be used to study neurological diseases .

Cat. No.	Product Name	Target	Research Area

HY-P4106A

*Tat-GluR23Y, scrambled TFA* 1 Publications Verification	Amino Acid Derivatives	Neurological Disease
Tat-GluR23Y, scrambled TFA is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .

HY-P1195

PDZ1 Domain inhibitor peptide	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P1399A

Pep2m, myristoylated TFA Myr-Pep2m TFA	PKC	Neurological Disease
Pep2m, myristoylated TFA (Myr-Pep2m TFA) is a cell-permeable peptide. Pep2m, myristoylated TFA can disrupt the protein kinase ζ (PKMζ) downstream targets, *N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions*. PKMζ is an autonomously active isozyme of protein kinase C (PKC) .

HY-P5487

GluR23Y	iGluR	Others
GluR23Y is a biological active peptide. (This GluR23Y peptide was used in ELISA cell-surface assay for the insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y prevented any insulin-induced reduction. The blockade of insulin action was observed when the GluR23Y peptide was delivered into neurons by fusing it to the membrane transduction domain of HIV-1.)

HY-P10401

*TAT-GluR6-9c*	Apoptosis iGluR	Cardiovascular Disease Neurological Disease
TAT-GluR6-9c is a *GluR6-PSD95* interaction blocker. By regulating the *GluR6* mediated signaling pathway, TAT-GluR6-9c inhibits the activation of JNK and phosphorylation of c-Jun, reduces the expression of Fas L and thus reduces the occurrence of apoptosis. TAT-GluR6-9c can be used to study cerebral ischemia and neuroprotective strategies .

HY-P5395

*TAT-GluR23A Fusion Peptide*	HIV	Others
TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)

HY-P4106

*Tat-GluR23Y, scrambled*	Amino Acid Derivatives	Neurological Disease
Tat-GluR23Y, scrambled is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .

HY-P1195A

PDZ1 Domain inhibitor peptide TFA	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P1055

Pep2-SVKE	iGluR	Neurological Disease
Pep2-SVKE is an inactive control peptide for pep2-SVKI (HY-P1056). Pep2-SVKE is an inhibitory peptide corresponding to the last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. Pep2-SVKE does not block AMPA-mediated [ ³H]DA exocytosis. Pep2-SVKE does not bind to GRIP or PICK43 and does not block retention of PICK1 by GST-GluR2 and LTD ^{[1] [2] [3] [4] [5]}.

HY-P1399

Pep2m, myristoylated Myr-Pep2m	PKC	Neurological Disease
Pep2m, myristoylated (Myr-Pep2m) is a cell-permeable peptide. Pep2m, myristoylated can disrupt the protein kinase ζ (PKMζ) downstream targets, *N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions*. PKMζ is an autonomously active isozyme of protein kinase C (PKC) .

HY-P1059

Pep2-AVKI	iGluR	Neurological Disease
Pep2-AVKI is a selective peptide inhibitor of the binding of the AMPA receptor subunit (GluR2) at the C-terminal PDZ site to C-kinase (PICK1). Pep2-AVKI does not affect the binding of (AMPA-type glutamate receptor) GluA2 to GRIP or ABP. Pep2-AVKI does not increase the amplitude of AMPA currents. pep2-AVKI can be used to study neurological diseases .

Cat. No.	Product Name	Target	Research Area

HY-P3504

Efinopegdutide JNJ-64565111; HM12525A; MK-6024	GCGR iGluR	Metabolic Disease
Efinopegdutide (JNJ-64565111) is a potent dual glucagon-like peptide-1 (GLP-1)/glucagon receptor (GluR) agonist, which activates both the GLP-1 and glucagon receptors. Efinopegdutide can be used in research of nonalcoholic steatohepatitis (NASH) .

Cat. No.	Compare	Product Name	Species	Source

HY-P75156

	GRIK2 Protein, Human (HEK293, hFc) Glutamate receptor ionotropic, kainate 2; GluK2; EAA4; GluR6	Human	HEK293
	GRIK2 is an ionotropic glutamate receptor that plays an important role in central nervous system synapses, responding to L-glutamate as an excitatory neurotransmitter. Upon binding of L-glutamate, GRIK2 undergoes a conformational change that opens cation channels that convert chemical signals into electrical impulses. GRIK2 Protein, Human (HEK293, hFc) is the recombinant human-derived GRIK2 protein, expressed by HEK293 , with C-hFc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0122S

Topiramate-13C6

Topiramate-13C6 (McN 4853-13C6) is the ¹³C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-B0122S1

Topiramate-13C

Topiramate- ¹³C (McN 4853- ¹³C) is ¹³C labeled Topiramate. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81398

	Ionotropic Glutamate Receptor 2 Antibody (YA1143) GRIA2; GluR2; Glutamate receptor 2; GluR-2; AMPA-selective glutamate receptor 2; GluR-B; GluR-K2; Glutamate receptor ionotropic; AMPA 2; GluA2	IHC-P	Human
	Ionotropic Glutamate Receptor 2 Antibody (YA1143) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Ionotropic Glutamate Receptor 2.

HY-P82336

	Phospho-Glutamate Receptor 1 (AMPA Subtype) (Ser845) Antibody (YA2081) GRIA1; GLUH1; GluR1; Glutamate receptor 1; GluR-1; AMPA-selective glutamate receptor 1; GluR-A; GluR-K1; Glutamate receptor ionotropic; AMPA 1; GluA1	WB	Human, Rat
	Phospho-Glutamate Receptor 1 (AMPA Subtype) (Ser845) Antibody (YA2081) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Glutamate Receptor 1 (AMPA Subtype) (Ser845).

HY-P85188

	GluR-3 Antibody (YA4880) GRIA3; GluR3; GluRC; Glutamate receptor 3; GluR-3; AMPA-selective glutamate receptor 3; GluR-C; GluR-K3; Glutamate receptor ionotropic; AMPA 3; GluA3	WB, IHC-P, ICC/IF, ELISA	Human
	GluR-3 Antibody (YA4880) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to GluR-3.

HY-P84316

	Ionotropic Glutamate Receptor 2 Antibody (YA4013) GluA2; GluR2; GluR-B; GluR-K2	WB, FC, ELISA	Human
	Ionotropic Glutamate Receptor 2 Antibody (YA4013) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Ionotropic Glutamate Receptor 2.

HY-P84525

	GRIK3 Antibody (YA4222) EAA5; GLR7; GluR7; GluK3; GluR7a	ICC/IF, ELISA	Human
	GRIK3 Antibody (YA4222) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GRIK3.

HY-P84526

	GRIK3 Antibody (YA4223) EAA5; GLR7; GluR7; GluK3; GluR7a	WB, FC, ELISA	Human
	GRIK3 Antibody (YA4223) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GRIK3.

HY-P82144

	GluA4 Antibody (YA1889) AMPA4; GluA4; GluR4; GluR4C; GluRD; Gria4	WB, FC	Human, Mouse, Rat
	GluA4 Antibody (YA1889) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GluA4.

HY-P84317

	Ionotropic Glutamate Receptor 2 Antibody (YA4014) GluR2; GluRB; GluA2; HBGR2; GluR-K2	IHC-P, FC, ELISA	Human
	Ionotropic Glutamate Receptor 2 Antibody (YA4014) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Ionotropic Glutamate Receptor 2.

HY-P86115

	Glutamate Receptor 1 (AMPA Subtype) Antibody (YA5807) GRIA1; GLUH1; GluR1; Glutamate receptor 1; GluR-1; AMPA-selective glutamate receptor 1; GluR-A; GluR-K1; Glutamate receptor ionotropic; AMPA 1; GluA1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Glutamate Receptor 1 (AMPA Subtype) Antibody (YA5807) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Glutamate Receptor 1 (AMPA Subtype).

HY-P83787

	GRM8 Antibody (YA3484) GluR8; mGlu8; GPRC1H; MGluR8	WB, FC, ELISA	Human
	GRM8 Antibody (YA3484) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GRM8.

HY-P82960

	GRIK2 Antibody (YA2705) EAA4; GLR6; MRT6; GLUK6; GluR6; GluK2	WB, IHC-P	Human, Mouse, Rat
	GRIK2 Antibody (YA2705) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GRIK2.

HY-P84569

	Metabotropic Glutamate Receptor 2 Antibody (YA4266) GluR2; mGlu2; GPRC1B; MGluR2	WB, FC, ELISA	Human
	Metabotropic Glutamate Receptor 2 Antibody (YA4266) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Metabotropic Glutamate Receptor 2.

HY-P84577

	GRM7 Antibody (YA4274) GluR7; MGLU7; GPRC1G; MGluR7; PPP1R87	ICC/IF, FC, ELISA	Human
	GRM7 Antibody (YA4274) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GRM7.

HY-P84578

	Metabotropic Glutamate Receptor 3 Antibody (YA4275) GluR3; mGlu3; GPRC1C; MGluR3	IHC-P, ICC/IF, FC, ELISA	Human
	Metabotropic Glutamate Receptor 3 Antibody (YA4275) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Metabotropic Glutamate Receptor 3.

HY-P83232

	Metabotropic Glutamate Receptor 3 Antibody (YA2977) GluR3; GPRC1C; GRM3; MGlu3; mGluR3	WB	Human, Mouse, Rat
	Metabotropic Glutamate Receptor 3 Antibody (YA2977) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Metabotropic Glutamate Receptor 3.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-148828

LSP-GR3		Antisense Oligonucleotides
LSP-GR3 is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate *GluR* alternative splicing to GluR3-flip expression throughout the CNS.

HY-148828A

LSP-GR3 sodium		Antisense Oligonucleotides
LSP-GR3 sodium is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate *GluR* alternative splicing to GluR3-flip expression throughout the CNS.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: